Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department has taken to secure supplies of Jynneos, also known as Imvanex and Imvamune, or other vaccines used for monkeypox.

Although it is not specifically licensed for the prevention of monkeypox in Europe, the smallpox vaccine Imvanex has been used in the United Kingdom in response to previous incidents. This vaccine has demonstrated that it is highly effective at preventing infection when administered within four days of exposure and reducing severe illness between four and 14 days of exposure. The UK Health Security Agency (UKHSA) has recommended the use of the vaccination for named close contacts of cases and eligibility is kept under review. The UKHSA is working with suppliers, including Bavarian Nordic, which manufactures Imvanex, to ensure a consistent supply.